Business context and reporting period
Profound Medical Corp. filed this Form 8-K on October 9, 2026, to announce that it entered into a co-education agreement with Telix Pharmaceuticals Limited. The filing does not describe the agreement’s scope or terms; it refers to a press release furnished as Exhibit 99.1, which is not included in the supplied text.
Financial performance and liquidity
This filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial results.
Material changes versus prior period
No financial or operational comparisons with a prior period are provided.
Outlook, risks, and unusual items
No guidance, outlook, risks, contingencies, or financial impact of the agreement are disclosed in the supplied filing text.
The announcement and exhibit are furnished under Item 7.01 and are not deemed filed for purposes of Exchange Act Section 18 or incorporated by reference into other filings, as described in the report.
Investor verification points
- Review Exhibit 99.1 for the agreement’s purpose, activities, duration, and any financial or operational commitments.
- Verify whether the agreement is expected to affect Profound Medical’s results, costs, or commercial plans.